SBIR-STTR Award

Chloride Channel Blockers As Neuroprotective Agents
Award last edited on: 4/7/06

Sponsored Program
SBIR
Awarding Agency
NIH : NINDS
Total Award Amount
$849,984
Award Phase
2
Solicitation Topic Code
-----

Principal Investigator
Paul J Marangos

Company Information

Questcor Pharmaceuticals (AKA: Ribogene Inc~Cypros~Transgene~NeuroTherapeutics)

3260 Whipple Road
Union City, CA 94587
   (510) 400-0700
   sales@questcor.com
   www.questcor.com
Location: Multiple
Congr. District: 15
County: Alameda

Phase I

Contract Number: 1R43NS35385-01A1
Start Date: 00/00/00    Completed: 00/00/00
Phase I year
1997
Phase I Amount
$100,000
One consequence of traumatic (head injury) and ischemic (stroke) brain injury that has been largely ignored in therapeutics development is glial swelling. Glial (astrocytic) swelling causes impingement on blood capillaries, reducing the flow of oxygen and nutrients to brain cells, and causes astrocytes to release, rather than take up, neurotransmitters, further potentiating neurologic damage. The swelling phenomenon is mediated by a Cl- -dependent mechanism, involving influx of Cl- ions into the glia. L-644,711, a fluorenone derivative of ethacrynic acid, is a potent inhibitor of astrocytic Cl- channels and has been shown to be neuroprotective in models of traumatic injury both in vitro and in vivo. We propose to examine whether L-644,711, an amidine derivative of it and four novel derivatives are able to reduce astrocytic swelling and neurotransmitter release in vitro, and whether L-644,711 and the derivative deemed most promising as indicated by the in vitro data are neuroprotective in in vivo models of focal and global ischemia.

Thesaurus Terms:
cerebral ischemia /hypoxia, chloride channel, drug design /synthesis /production, inhibitor /antagonist, method development, neuroprotectant astrocyte, ethacrynate, neurotransmitter biosynthesis, pathologic process laboratory rat, tissue /cell cultureNational Institute of Neurological Disorders and Stroke (NINDS)

Phase II

Contract Number: 2R44NS035385-02
Start Date: 00/00/00    Completed: 00/00/00
Phase II year
1999
(last award dollars: 2000)
Phase II Amount
$749,984

One consequence of traumatic (head injury) and ischemic (stroke) brain injury that has been largely ignored in therapeutics development is glial swelling. Glial (astrocytic) swelling causes impingement on blood capillaries, reducing the flow of oxygen and nutrients to brain cells, and causes astrocytes to release, rather than take up, neurotransmitters, further potentiating neurologic damage. The swelling phenomenon is mediated by a Cl- -dependent mechanism, involving influx of Cl- ions into the glia. L-644,711, a fluorenone derivative of ethacrynic acid, is a potent inhibitor of astrocytic Cl- channels and has been shown to be neuroprotective in models of traumatic injury both in vitro and in vivo. We propose to examine whether L-644,711, an amidine derivative of it and four novel derivatives are able to reduce astrocytic swelling and neurotransmitter release in vitro, and whether L-644,711 and the derivative deemed most promising as indicated by the in vitro data are neuroprotective in in vivo models of focal and global ischemia.

Thesaurus Terms:
cerebral ischemia /hypoxia, chloride channel, drug design /synthesis /production, ion channel blocker, method development, neuroprotectant astrocyte, excitatory aminoacid, head /neck injury, neurotransmitter biosynthesis, pharmacokinetics, trauma chemical synthesis, laboratory rat, tissue /cell culture